Vor Biopharma (VOR) Fundamentals 2026 — Revenue Analysis | SniperIQ
Vor Biopharma (VOR) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Vor Biopharma's market cap?
Vor Biopharma (VOR) has a market capitalization of approximately
How profitable is Vor Biopharma?
Vor Biopharma runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Vor Biopharma pay a dividend?
Vor Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Vor Biopharma financially healthy?
Vor Biopharma carries a debt-to-equity ratio of -0.02x and a current ratio of 31.15x, with a market beta of 1.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Vor Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vor Biopharma (VOR) the key facts are: market cap
Track Vor Biopharma's full fundamentals live
Get Vor Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.